The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus

Launched by AIN SHAMS UNIVERSITY · Jul 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether taking a supplement called coenzyme Q10 can help children and teenagers with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body and can cause serious health problems. The researchers want to find out if coenzyme Q10 can improve how the cells’ energy centers (called mitochondria) work and if it can reduce the activity and symptoms of lupus. To do this, some participants will take coenzyme Q10 along with their usual lupus treatment, while others will receive only the usual treatment, and the results will be compared over three months.

Children and teens between 6 and 16 years old who have been diagnosed with moderate to severe lupus, especially those with kidney involvement (lupus nephritis), may be eligible to join. Participants should be physically stable and not currently taking other antioxidant supplements like vitamin E or omega-3s. If accepted, they will take their assigned treatment daily and visit the clinic every four weeks for checkups and tests. This study is currently recruiting, and it aims to find out if adding coenzyme Q10 is a safe and helpful way to better manage lupus in young patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Both genders aged 6-16 years old diagnosed with SLE according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria of SLE.
• • 2. Patients with moderate to severe activity presenting with lupus nephritis.
• • 3. No enrollment in any other clinical trial.
• • 4. Judged by the physician to be physically stable.
• Exclusion Criteria:
• • 1. Patients taking over-the-counter antioxidants such as N-acetylcysteine, vitamin E, omega-3 fatty acids, L-carnitine or vitamin C that can enhance the effect of CoQ10.
• • 2. Patients with very severe active SLE that might threaten vital organs.
• • 3. Patients with chronic infections, severe and recurrent infections whether bacterial, viral, or fungal infection